Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid-lowering arm extension

Journal of Hypertension

Volumn 27, Issue 5, 2009, Pages 947-954

  Sever, Peter S ^a   Poulter, Neil R ^a   Dahlof, Bjorn ^b   Wedel, Hans ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

Antihypertensive drugs; Atorvastatin; Cardiovascular outcomes; Coronary heart disease

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CHOLESTEROL; PERINDOPRIL; PLACEBO;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 67649669799     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328326cb1a     Document Type: Article

References (11)

1. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
2. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al., on behalf of the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 24:2982-2988.
3. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
4. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., the ASCOT Steering Committee Members. The Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm: extended observations 2 years after trial closure. Euro Heart J 2008; 29:499-508.
5. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al., on behalf of the ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19:1139-1147.
6. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al., on behalf of the Scandinavian Simvastatin Survival Study Group. Follow-up study of patients randomised in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am J Cardiol 2000; 86:257-262.
7. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359:1379-1387.
8. Ford I, Murray H, Packard CJ, Shephard J, Macfarlane PW, Cobbe SM. Long-term follow up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486.
9. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al., for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907-913.
10. Munro E, Patel M, Chan P, Betteridge L, Clunn G, Gallagher K, et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994; 24:766-772.
11. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic action. Am J Cardiol 2005; 96:11F-23F.